Shahram Ala
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shahram Ala has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
Fatemeh Heydari
Department of Anesthesiology, School of Medicine, Sari Imam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Iran
4 shared publicationsAbbas Alipour
Mazandaran Univ Med Sci, Thalassemia Res Ctr, Sari, Iran
3 shared publications- Ebrahim Salehifar
Pharmaceutical Sciences Research Center, Institute of Herbal Medicines and Metabolic Disorders, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran
3 shared publications Saeid Abediankenari
Mazandaran Univ Med Sci, Fac Med, Dept Immunol, Sari, Iran
3 shared publicationsAdeleh Sahebnasagh
Clinical Research Center, Department of Internal Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran
2 shared publications- Adeleh Sahebnasagh
Clinical Research Center, Department of Internal Medicine, Faculty of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran
2 shared publications
Latest Publications
- Open Access
- 1 February 2026
- Published by Wolters Kluwer Health in Journal of Research in Pharmacy Practice
- Vol. 15 (1)
Evaluation of the Effect of Mechanical Ventilation on the Pharmacokinetic Parameters of Vancomycin in Intensive Care Patients: A Prospective Cohort Study
Objective: Intensive care unit (ICU) patients on mechanical ventilation, in particular, may experience changes in pharmacokinetics due to alterations in cardiac output and organ blood flow. This study aims to evaluate the effects of mechanical ventilation on the steady-state pharmacokinetic changes of vancomycin. Methods: In this prospective cohort study, eligible patients were enrolled into either the ventilated or non-ventilated group. Demographic and clinical data were gathered, and peak and trough blood samples were collected to measure their levels. Additional pharmacokinetic parameters were calculated using appropriate formulas. Findings: A total of 39 ICU patients were enrolled in the final analysis. Of these, 32 matched patients were divided into two equal groups: ventilated and nonventilated. None of the pharmacokinetic parameters, including peak plasma concentration ( P = 0.878), trough plasma concentration ( P = 0.437), volume of distribution ( P = 0.468), K ( P = 0.234), t ½ ( P = 0.266), clearance ( P = 0.709), and daily area under the curve ( P = 0.418), were significantly different between the two groups. Bivariate correlation analysis showed a significant correlation between estimated glomerular filtration rate, acute physiology and chronic health evaluation II score, and C-reactive protein (CRP) level with vancomycin pharmacokinetic parameters. Furthermore, significant effects of augmented renal clearance (ARC) on vancomycin pharmacokinetics were determined. Conclusion: The key finding of this study was that ARC significantly impacted vancomycin serum levels, resulting in subtherapeutic concentrations in 23.1% of patients. High CRP levels also significantly correlated with increased vancomycin distribution volume, emphasizing the role of inflammation. These findings underscore the importance of personalized vancomycin dosing, taking into account factors such as ARC and inflammation, to improve patient outcomes. However, due to the small sample size, further studies with larger cohorts are necessary.
- 1 February 2026
- Published by Wolters Kluwer Health in Journal of Research in Pharmacy Practice
- Vol. 15 (1)
Open AccessEvaluation of the Effect of Mechanical Ventilation on the Pharmacokinetic Parameters of Vancomycin in Intensive Care Patients: A Prospective Cohort Study
Objective: Intensive care unit (ICU) patients on mechanical ventilation, in particular, may experience changes in pharmacokinetics due to alterations in cardiac output and organ blood flow. This study aims to evaluate the effects of mechanical ventilation on the steady-state pharmacokinetic changes of vancomycin. Methods: In this prospective cohort study, eligible patients were enrolled into either the ventilated or non-ventilated group. Demographic and clinical data were gathered, and peak and trough blood samples were collected to measure their levels. Additional pharmacokinetic parameters were calculated using appropriate formulas. Findings: A total of 39 ICU patients were enrolled in the final analysis. Of these, 32 matched patients were divided into two equal groups: ventilated and nonventilated. None of the pharmacokinetic parameters, including peak plasma concentration ( P = 0.878), trough plasma concentration ( P = 0.437), volume of distribution ( P = 0.468), K ( P = 0.234), t ½ ( P = 0.266), clearance ( P = 0.709), and daily area under the curve ( P = 0.418), were significantly different between the two groups. Bivariate correlation analysis showed a significant correlation between estimated glomerular filtration rate, acute physiology and chronic health evaluation II score, and C-reactive protein (CRP) level with vancomycin pharmacokinetic parameters. Furthermore, significant effects of augmented renal clearance (ARC) on vancomycin pharmacokinetics were determined. Conclusion: The key finding of this study was that ARC significantly impacted vancomycin serum levels, resulting in subtherapeutic concentrations in 23.1% of patients. High CRP levels also significantly correlated with increased vancomycin distribution volume, emphasizing the role of inflammation. These findings underscore the importance of personalized vancomycin dosing, taking into account factors such as ARC and inflammation, to improve patient outcomes. However, due to the small sample size, further studies with larger cohorts are necessary.
- Open Access
- 1 January 2025
- Published by Wolters Kluwer Health in Journal of Research in Pharmacy Practice
- Vol. 14 (1) , 9-17
Comparison of the Efficacy of Adding Inhaled Levofloxacin and Colistin to a Basic Regimen of Colistin and Meropenem in the Treatment of Ventilator-associated Pneumonia Caused by Multidrug-resistant Gram-negative Bacteria: A Randomized Open-label Clinical Trial
Objective: Ventilator-associated pneumonia (VAP) caused by multidrug-resistant Gram-negative bacteria (MDR-GNB) is a major intensive care unit challenge, particularly in Iran, due to limited antibiotic options. This study compared the efficacy of adding levofloxacin and colistin inhalation form to the baseline regimen of colistin and meropenem in treating VAP caused by MDR-GNB. Methods: Patients with VAP were randomly assigned to the colistin group ( n = 24), receiving 2 million international unit (MIU) every 8 h, and the levofloxacin group ( n = 22), receiving 250 mg every 12 h, alongside intravenous colistin (4.5 MIU every 12 h) and meropenem (1 g every 8 h). Clinical improvement using the Clinical Pulmonary Infection Score (CPIS) on days 1, 5, and 7, the clinical response on day 7, and inflammatory markers (erythrocyte sedimentation rate and C-reactive protein) on days 1, 3, 5, and 7 were evaluated. Findings: CPIS scores significantly decreased in both groups: Colistin (−3.67 ± 2.14, P < 0.001) and levofloxacin (−4.41 ± 1.71, P < 0.001), with no intergroup difference ( P = 0.200). The clinical response analysis indicated that levofloxacin was associated with fewer treatment failures and more partial responses, whereas colistin demonstrated higher rates of complete response; however, these differences were not statistically significant ( P > 0.05). Acute kidney injury occurred only in the colistin group ( n = 8; 33.3%). Bronchospasm and cough occurred in one levofloxacin patient (4.54%), showing a significant difference in adverse effects ( P = 0.004). Mortality rates were higher in the colistin group ( n = 17; 70.8%) compared to the levofloxacin group ( n = 10; 45.5%), though this difference was not statistically significant ( P = 0.08). Conclusion: Levofloxacin inhalation may be considered an effective alternative to colistin inhalation for treating VAP caused by MDR-GNB. It offers similar efficacy and lower nephrotoxicity.
- 1 January 2025
- Published by Wolters Kluwer Health in Journal of Research in Pharmacy Practice
- Vol. 14 (1) , 9-17
Open AccessComparison of the Efficacy of Adding Inhaled Levofloxacin and Colistin to a Basic Regimen of Colistin and Meropenem in the Treatment of Ventilator-associated Pneumonia Caused by Multidrug-resistant Gram-negative Bacteria: A Randomized Open-label Clinical Trial
Objective: Ventilator-associated pneumonia (VAP) caused by multidrug-resistant Gram-negative bacteria (MDR-GNB) is a major intensive care unit challenge, particularly in Iran, due to limited antibiotic options. This study compared the efficacy of adding levofloxacin and colistin inhalation form to the baseline regimen of colistin and meropenem in treating VAP caused by MDR-GNB. Methods: Patients with VAP were randomly assigned to the colistin group ( n = 24), receiving 2 million international unit (MIU) every 8 h, and the levofloxacin group ( n = 22), receiving 250 mg every 12 h, alongside intravenous colistin (4.5 MIU every 12 h) and meropenem (1 g every 8 h). Clinical improvement using the Clinical Pulmonary Infection Score (CPIS) on days 1, 5, and 7, the clinical response on day 7, and inflammatory markers (erythrocyte sedimentation rate and C-reactive protein) on days 1, 3, 5, and 7 were evaluated. Findings: CPIS scores significantly decreased in both groups: Colistin (−3.67 ± 2.14, P < 0.001) and levofloxacin (−4.41 ± 1.71, P < 0.001), with no intergroup difference ( P = 0.200). The clinical response analysis indicated that levofloxacin was associated with fewer treatment failures and more partial responses, whereas colistin demonstrated higher rates of complete response; however, these differences were not statistically significant ( P > 0.05). Acute kidney injury occurred only in the colistin group ( n = 8; 33.3%). Bronchospasm and cough occurred in one levofloxacin patient (4.54%), showing a significant difference in adverse effects ( P = 0.004). Mortality rates were higher in the colistin group ( n = 17; 70.8%) compared to the levofloxacin group ( n = 10; 45.5%), though this difference was not statistically significant ( P = 0.08). Conclusion: Levofloxacin inhalation may be considered an effective alternative to colistin inhalation for treating VAP caused by MDR-GNB. It offers similar efficacy and lower nephrotoxicity.
- Open Access
- 14 February 2023
- Published by Brieflands in Journal of Nursing and Midwifery Sciences
- Vol. 10 (1)
The Effects of Memantine on the Glasgow Coma Scale, Sequential Organ Failure Assessment Score, and Neuron-Specific Enolase Serum Levels in Traumatic Brain Injury Patients
Background: Traumatic brain injury (TBI) causes disability and death in many patients. Objectives: We investigated the effect of memantine on the Glasgow Coma Scale (GCS), serum levels of neuron-specific enolase (NSE), and its effect on sequential organ failure assessment (SOFA) score in TBI patients with GCS 6-12 on days 1, 3, and 7. Methods: Fifty-nine patients were randomly divided into intervention (n = 29) and control (n = 30) groups who received 30mg drug/placebo every 12 hours for seven days with standard treatment, respectively. The acute physiology and chronic health evaluation II and head CT scan findings were collected on the first day, and the Glasgow Outcome Scale Extended 90 was collected three months later. Results: Considering patients with GCS 6 - 12, the SOFA and NSE decreased from day 1 - 7 in both memantine and control groups, about NSE by 21% and 12.6%, respectively. In GCS6-8 subgroup, the NSE decreased by 19.1% in the memantine group and increased by 8.45%, in the control group. In GCS 9 - 12 subgroup, the NSE decreased by 52.6% and 24.43% in the memantine and control groups, respectively. The SOFA changes were significant between memantine and control groups on day 3 in GCS 9 - 12 subgroup (P = 0.01). In the memantine group with GCS 6 - 12, the increase of GCS from day 1 - 7 was significant (29.6%, P = 0.002), and also in both GCS subgroups. Comparing memantine and control groups, the improvement of GCS was significant on days 3 and 7 in GCS 9 - 12 subgroup. Conclusions: This trial showed that memantine improved the neurohormonal and clinical status of TBI patients with GCS 6 - 12.
- 14 February 2023
- Published by Brieflands in Journal of Nursing and Midwifery Sciences
- Vol. 10 (1)
Open AccessThe Effects of Memantine on the Glasgow Coma Scale, Sequential Organ Failure Assessment Score, and Neuron-Specific Enolase Serum Levels in Traumatic Brain Injury Patients
Background: Traumatic brain injury (TBI) causes disability and death in many patients. Objectives: We investigated the effect of memantine on the Glasgow Coma Scale (GCS), serum levels of neuron-specific enolase (NSE), and its effect on sequential organ failure assessment (SOFA) score in TBI patients with GCS 6-12 on days 1, 3, and 7. Methods: Fifty-nine patients were randomly divided into intervention (n = 29) and control (n = 30) groups who received 30mg drug/placebo every 12 hours for seven days with standard treatment, respectively. The acute physiology and chronic health evaluation II and head CT scan findings were collected on the first day, and the Glasgow Outcome Scale Extended 90 was collected three months later. Results: Considering patients with GCS 6 - 12, the SOFA and NSE decreased from day 1 - 7 in both memantine and control groups, about NSE by 21% and 12.6%, respectively. In GCS6-8 subgroup, the NSE decreased by 19.1% in the memantine group and increased by 8.45%, in the control group. In GCS 9 - 12 subgroup, the NSE decreased by 52.6% and 24.43% in the memantine and control groups, respectively. The SOFA changes were significant between memantine and control groups on day 3 in GCS 9 - 12 subgroup (P = 0.01). In the memantine group with GCS 6 - 12, the increase of GCS from day 1 - 7 was significant (29.6%, P = 0.002), and also in both GCS subgroups. Comparing memantine and control groups, the improvement of GCS was significant on days 3 and 7 in GCS 9 - 12 subgroup. Conclusions: This trial showed that memantine improved the neurohormonal and clinical status of TBI patients with GCS 6 - 12.
- Open Access
Acute pancreatitis following COVID-19 vaccine: A case report and brief literature review
- Open Access
- 1 January 2022
- Vol. 13 (1) , 51-60
Effect of melatonin on stress-induced hyperglycemia and insulin resistance in critically-ill patients: A randomized double-blind, placebo-controlled clinical trial
Background: Hyperglycemia is a common finding which is associated with increased mortality and morbidity among critically ill patients. There is currently no evidence that melatonin could improve stress induced hyperglycemia (SIH). In this study, we evaluated the effect of melatonin on blood sugar and insulin resistance (IR) in critically-ill patients. Methods: 104 critically-ill patients with SIH divided into two groups, receiving melatonin (6 mg BD for 3 days) or placebo. Changes of blood sugar, IR indices including homeostasis model assessment for insulin resistance and homeostasis model assessment adiponectin (HOMA-AD) ratios, Glasgow coma scale (GCS) were evaluated on the 4th day of melatonin prescription. On the 7Th day of study, changes of ventilator dependency and delirium were considered. Mortality and intensive care unit (ICU) stay were also compared between groups. Results: On day 4, patients in the melatonin group had significantly lower blood glucose and HMOA-IR level compared with the placebo group (P=0.04 and P=0.03, respectively) whereas HOMA-AD level did not differ significantly from placebo group (p>0.2). Also, we did not observe any significant difference in GCS level at this time between groups (p>0.2). On day 7, melatonin could not improve ventilator dependency and delirium significantly (p>0.2) and also could not reduce mortality and ICU stay in comparison with placebo (p>0.2, P=0.2, respectively). Conclusion: Melatonin supplementation showed positive effect on blood sugar and somehow insulin resistance whereas it could not improve ICU complications.
- 1 January 2022
- Vol. 13 (1) , 51-60
Open AccessEffect of melatonin on stress-induced hyperglycemia and insulin resistance in critically-ill patients: A randomized double-blind, placebo-controlled clinical trial
Background: Hyperglycemia is a common finding which is associated with increased mortality and morbidity among critically ill patients. There is currently no evidence that melatonin could improve stress induced hyperglycemia (SIH). In this study, we evaluated the effect of melatonin on blood sugar and insulin resistance (IR) in critically-ill patients. Methods: 104 critically-ill patients with SIH divided into two groups, receiving melatonin (6 mg BD for 3 days) or placebo. Changes of blood sugar, IR indices including homeostasis model assessment for insulin resistance and homeostasis model assessment adiponectin (HOMA-AD) ratios, Glasgow coma scale (GCS) were evaluated on the 4th day of melatonin prescription. On the 7Th day of study, changes of ventilator dependency and delirium were considered. Mortality and intensive care unit (ICU) stay were also compared between groups. Results: On day 4, patients in the melatonin group had significantly lower blood glucose and HMOA-IR level compared with the placebo group (P=0.04 and P=0.03, respectively) whereas HOMA-AD level did not differ significantly from placebo group (p>0.2). Also, we did not observe any significant difference in GCS level at this time between groups (p>0.2). On day 7, melatonin could not improve ventilator dependency and delirium significantly (p>0.2) and also could not reduce mortality and ICU stay in comparison with placebo (p>0.2, P=0.2, respectively). Conclusion: Melatonin supplementation showed positive effect on blood sugar and somehow insulin resistance whereas it could not improve ICU complications.
- Open Access
- 6 January 2021
- Published by Springer Nature in Journal of Pharmaceutical Health Care and Sciences
- Vol. 7 (1) , 1-8
The comparison of the effect of flaxseed oil and vitamin E on mastalgia and nodularity of breast fibrocystic: a randomized double-blind clinical trial
Background: Fibrocystic changes are a common benign condition in women aged 20–50. The medical intervention aims to stop fibrocystic disease progress and relieve the breast’s pain and tenderness. In the long-term, reversing the fibrocystic changes is also desirable. Methods: In this randomized double-blind clinical trial, the effect of flaxseed oil on the severity of pain and breast nodularity was investigated against vitamin E. This study was conducted on 100 women with mastalgia. The intervention group received Flaxseed oil pearls and the control group received vitamin E pearl 200 IU twice a day for 2 months. The duration and severity of breast pain were evaluated by Cardiff chart and VAS (Visual Analogue Scale). The nodularity was assessed by Lucknow-Cardiff scale at baseline, then the first and second months of intervention. Results: At baseline, there was no statistically significant difference between the two groups in characteristics. The breast pain improved in both groups during the first and second months of intervention (P-value within group< 0.001). However, the mean breast pain was not significantly different between the two groups at the end of the first and second month (P1= 0.54, P2= 0.73). Furthermore, the breast pain during four phases of the menstrual cycle showed no difference between vitamin E and flaxseed oil groups (menstruation phase= 0.76, follicular phase= 0.48, the first week of luteal phase= 0.86, the second week of luteal phase=0.30). The breast nodularity also decreased during the first and second months of intervention, yet no significant difference between the two groups was found (p= 0.9). Conclusions: This study showed that flaxseed oil and vitamin E both could be effective in breast pain-relieving and decreasing nodularity with minimal side effects in contrast with the baseline. But there are no significant differences between these two agents. Larger scale prospective studies are needed to evaluate these effects in the long-term. Trial registration: IRCT201612243014N18, Registration date: 2017-10-15.
- 6 January 2021
- Published by Springer Nature in Journal of Pharmaceutical Health Care and Sciences
- Vol. 7 (1) , 1-8
Open AccessThe comparison of the effect of flaxseed oil and vitamin E on mastalgia and nodularity of breast fibrocystic: a randomized double-blind clinical trial
Background: Fibrocystic changes are a common benign condition in women aged 20–50. The medical intervention aims to stop fibrocystic disease progress and relieve the breast’s pain and tenderness. In the long-term, reversing the fibrocystic changes is also desirable. Methods: In this randomized double-blind clinical trial, the effect of flaxseed oil on the severity of pain and breast nodularity was investigated against vitamin E. This study was conducted on 100 women with mastalgia. The intervention group received Flaxseed oil pearls and the control group received vitamin E pearl 200 IU twice a day for 2 months. The duration and severity of breast pain were evaluated by Cardiff chart and VAS (Visual Analogue Scale). The nodularity was assessed by Lucknow-Cardiff scale at baseline, then the first and second months of intervention. Results: At baseline, there was no statistically significant difference between the two groups in characteristics. The breast pain improved in both groups during the first and second months of intervention (P-value within group< 0.001). However, the mean breast pain was not significantly different between the two groups at the end of the first and second month (P1= 0.54, P2= 0.73). Furthermore, the breast pain during four phases of the menstrual cycle showed no difference between vitamin E and flaxseed oil groups (menstruation phase= 0.76, follicular phase= 0.48, the first week of luteal phase= 0.86, the second week of luteal phase=0.30). The breast nodularity also decreased during the first and second months of intervention, yet no significant difference between the two groups was found (p= 0.9). Conclusions: This study showed that flaxseed oil and vitamin E both could be effective in breast pain-relieving and decreasing nodularity with minimal side effects in contrast with the baseline. But there are no significant differences between these two agents. Larger scale prospective studies are needed to evaluate these effects in the long-term. Trial registration: IRCT201612243014N18, Registration date: 2017-10-15.
- Open Access
- 13 May 2020
- Published by Springer Nature in BMC Complementary Medicine and Therapies
- Vol. 20 (1) , 1-9
Prevention of acute radiation-induced Proctitis by Aloe vera: a prospective randomized, double-blind, placebo controlled clinical trial in Pelvic Cancer patients
Background: Acute radiation-induced proctitis (ARP) is the most common side effect following radiotherapy for malignant pelvic disease. This study evaluated the efficacy of Aloe vera ointment in prevention of ARP. Methods: Forty-two patients receiving external-beam radiotherapy (RT) for pelvic malignancies were randomized to receive either Aloe vera 3% or placebo topical ointment during radiotherapy for 6 weeks. These patients were evaluated based on the severity (grade 0–4) of the following symptoms weekly: rectal bleeding, abdominal/rectal pain, diarrhea, or fecal urgency. RTOG acute toxicity criteria and psychosocial status of the patients were also recorded weekly. Lifestyle impact of the symptoms, and quantitative measurement of C-reactive protein (CRP), an indicator of systemic inflammation, were also measured. Results: The results of present study demonstrated a significant preventive effect for Aloe vera in occurrence of symptom index for diarrhea (p < 0.001), rectal bleeding (p < 0.001), and fecal urgency (p = 0.001). The median lifestyle score improved significantly with Aloe vera during RT (p < 0.001). Intervention patients had a significant lower burden of systemic inflammation as the values for quantitative CRP decreased significantly over 6 weeks of follow-up (p = 0.009). Conclusion: This study showed that Aloe vera topical ointment was effective in prevention of symptoms of ARP in patients undergoing RT for pelvic cancers. Trial registration: IRCT201606042027N6. Registration date: 2016-09-04.
- 13 May 2020
- Published by Springer Nature in BMC Complementary Medicine and Therapies
- Vol. 20 (1) , 1-9
Open AccessPrevention of acute radiation-induced Proctitis by Aloe vera: a prospective randomized, double-blind, placebo controlled clinical trial in Pelvic Cancer patients
Background: Acute radiation-induced proctitis (ARP) is the most common side effect following radiotherapy for malignant pelvic disease. This study evaluated the efficacy of Aloe vera ointment in prevention of ARP. Methods: Forty-two patients receiving external-beam radiotherapy (RT) for pelvic malignancies were randomized to receive either Aloe vera 3% or placebo topical ointment during radiotherapy for 6 weeks. These patients were evaluated based on the severity (grade 0–4) of the following symptoms weekly: rectal bleeding, abdominal/rectal pain, diarrhea, or fecal urgency. RTOG acute toxicity criteria and psychosocial status of the patients were also recorded weekly. Lifestyle impact of the symptoms, and quantitative measurement of C-reactive protein (CRP), an indicator of systemic inflammation, were also measured. Results: The results of present study demonstrated a significant preventive effect for Aloe vera in occurrence of symptom index for diarrhea (p < 0.001), rectal bleeding (p < 0.001), and fecal urgency (p = 0.001). The median lifestyle score improved significantly with Aloe vera during RT (p < 0.001). Intervention patients had a significant lower burden of systemic inflammation as the values for quantitative CRP decreased significantly over 6 weeks of follow-up (p = 0.009). Conclusion: This study showed that Aloe vera topical ointment was effective in prevention of symptoms of ARP in patients undergoing RT for pelvic cancers. Trial registration: IRCT201606042027N6. Registration date: 2016-09-04.
- Open Access
- 1 January 2020
- Vol. 19 (1) , 111-119
Evaluation of Neuroprtective Effects of L-Carnitine and Fat Emulsion in the CVA Patients: A Prospective, Randomized, Double Blind, Clinical Trial
Cerebral infarction presents with neurological deficits caused by the death of neurons in a focal area of the brain. S 100B is a biomarker that increases in brain damage. Neuroproteciives can reduce the brain sequels after neurological insult. The purpose of this study was to evaluate the neuroprotective effects of L-carnitine and Fat emulsion (Lipofundin (R)) alone and in combination in patients with ischemic stroke. In a prospective, RCT. and double-blind study 100 patients with MCA ischemic cerebrovascular accident who were admitted in the first 24 h of injury entered the study. The patients were randomly assigned into four groups of L-carnitine, fat emulsion, L-carnitine plus fat emulsion and control. Fat emulsion 10%, 500 mL, was infused over 6 to 12 h and 1 gr of L-carnitine (10 mL of solution) was administered orally to patients in addition to common therapies, according to the American Heart Association and American Stroke Association (AHA/ASA) guidelines. The patients in the control group received only the usual treatment according to stroke guidelines. Blood samples before the intervention, then after 24 h, 48 h, and 7 days later were taken and immunoenzymatic colorimetric method was used for quantitative determination of S100B concentration in the patients' serum. In the within group analysis, all of our treatment interventions (except control group) have decreased S 100B levels statistically significant (P < 0.05). Moreover, changes in observed levels of S100B before and after intervention were different between the groups and the observed differences were statistically significant (P = 0.01). In the GEE model, it was found that S100B levels in the L-carnitine plus fat emulsion group decreased more than the control group and this decline has been statistically significant [P = 0.02, 20.47 (CI 95%: 6.25-34.41)] but in comparison of L-carnitine and fat emulsion group with control group, did not reached statistical significance (P > 0.05). Based on the results obtained from this study, it seems that L-carnitine with fat emulsion could lead to neuroprotective effects with a significant reduction in the S100B biomarker.
- 1 January 2020
- Vol. 19 (1) , 111-119
Open AccessEvaluation of Neuroprtective Effects of L-Carnitine and Fat Emulsion in the CVA Patients: A Prospective, Randomized, Double Blind, Clinical Trial
Cerebral infarction presents with neurological deficits caused by the death of neurons in a focal area of the brain. S 100B is a biomarker that increases in brain damage. Neuroproteciives can reduce the brain sequels after neurological insult. The purpose of this study was to evaluate the neuroprotective effects of L-carnitine and Fat emulsion (Lipofundin (R)) alone and in combination in patients with ischemic stroke. In a prospective, RCT. and double-blind study 100 patients with MCA ischemic cerebrovascular accident who were admitted in the first 24 h of injury entered the study. The patients were randomly assigned into four groups of L-carnitine, fat emulsion, L-carnitine plus fat emulsion and control. Fat emulsion 10%, 500 mL, was infused over 6 to 12 h and 1 gr of L-carnitine (10 mL of solution) was administered orally to patients in addition to common therapies, according to the American Heart Association and American Stroke Association (AHA/ASA) guidelines. The patients in the control group received only the usual treatment according to stroke guidelines. Blood samples before the intervention, then after 24 h, 48 h, and 7 days later were taken and immunoenzymatic colorimetric method was used for quantitative determination of S100B concentration in the patients' serum. In the within group analysis, all of our treatment interventions (except control group) have decreased S 100B levels statistically significant (P < 0.05). Moreover, changes in observed levels of S100B before and after intervention were different between the groups and the observed differences were statistically significant (P = 0.01). In the GEE model, it was found that S100B levels in the L-carnitine plus fat emulsion group decreased more than the control group and this decline has been statistically significant [P = 0.02, 20.47 (CI 95%: 6.25-34.41)] but in comparison of L-carnitine and fat emulsion group with control group, did not reached statistical significance (P > 0.05). Based on the results obtained from this study, it seems that L-carnitine with fat emulsion could lead to neuroprotective effects with a significant reduction in the S100B biomarker.
- Open Access
- 1 March 2019
- Published by Maad Rayan Publishing Company
- Vol. 18 (2) , 1086-1096
Effects of Minocycline on Neurological Outcomes In Patients With Acute Traumatic Brain Injury: A Pilot Study
Traumatic brain injury (TBI) is a public health problem worldwide. Secondary damage of brain injury begins within a few minutes after the trauma and can last a long time. It can be reversible, unlike primary injury. Therefore, therapeutic intervention can be used. The aims of this study were to assess the effects of minocycline on neurological function and serum S100B protein and neuron-specific enolase (NSE) levels in patients with moderate to severe TBI. Patients with acute onset of TBI and surgical evacuation of hematoma were randomized to receive either minocycline 100 mg orally twice daily or placebo for 7 days. The primary outcomes included changes in level of S100B and NSE at different time points during the trial. Additionally, changes in Glasgow coma scale (GCS) score were evaluated. The Glasgow Outcome Scale-Extended (GOS-E) score at 6 month after injury was assessed in discharge patients. Thirty four patients were randomized into the placebo (n=20) and treatment (n=14) groups. There was a marginal statistically significant differences in the normalized value of S100B between groups (p<0.1). The reduction in serum NSE level from baseline to day 5 was statistically significant (p=0.01) in minocycline group while it was not significantly decrease in placebo group (p=0.2). Also, GCS improvement over time within the minocycline group was significant (p=0.04) while was not significant in placebo group (p=0.11). The GOS-E scores were not significantly different between minocycline and placebo group. Based on this study, it seems that the use of minocycline may be effective in acute TBI.
- 1 March 2019
- Published by Maad Rayan Publishing Company
- Vol. 18 (2) , 1086-1096
Open AccessEffects of Minocycline on Neurological Outcomes In Patients With Acute Traumatic Brain Injury: A Pilot Study
Traumatic brain injury (TBI) is a public health problem worldwide. Secondary damage of brain injury begins within a few minutes after the trauma and can last a long time. It can be reversible, unlike primary injury. Therefore, therapeutic intervention can be used. The aims of this study were to assess the effects of minocycline on neurological function and serum S100B protein and neuron-specific enolase (NSE) levels in patients with moderate to severe TBI. Patients with acute onset of TBI and surgical evacuation of hematoma were randomized to receive either minocycline 100 mg orally twice daily or placebo for 7 days. The primary outcomes included changes in level of S100B and NSE at different time points during the trial. Additionally, changes in Glasgow coma scale (GCS) score were evaluated. The Glasgow Outcome Scale-Extended (GOS-E) score at 6 month after injury was assessed in discharge patients. Thirty four patients were randomized into the placebo (n=20) and treatment (n=14) groups. There was a marginal statistically significant differences in the normalized value of S100B between groups (p<0.1). The reduction in serum NSE level from baseline to day 5 was statistically significant (p=0.01) in minocycline group while it was not significantly decrease in placebo group (p=0.2). Also, GCS improvement over time within the minocycline group was significant (p=0.04) while was not significant in placebo group (p=0.11). The GOS-E scores were not significantly different between minocycline and placebo group. Based on this study, it seems that the use of minocycline may be effective in acute TBI.